Company intelligence / Profile preview
Tezcat Biosciences
New Haven, Connecticut, United Statestezcat.co ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Tezcat Biosciences is developing a novel class of protein-drug conjugates that exploit the macropinocytosis pathway to deliver cytotoxic payloads specifically to cancer cells with mutant RAS. Their technology is designed to be both indication and payload agnostic. The company’s lead program targets adult patients with mutant RAS-driven solid tumors and myeloma. Supported by academic collaborations and government awards, their platform is scalable for multiple indications.
- Therapeutic areas
- Oncology
- Modalities
- Protein-drug conjugateBiologicVaccine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Academic collaborations
Beyond the preview
Go deeper on Tezcat Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tezcat Biosciences.